114P Systemic inflammatory index as a prognostic biomarker in metastatic melanoma patients under immune checkpoint inhibitors

Pires, M. Rebordão; Caetano, A.C.; Costa, C.I. Amorim; Monteiro, J.C.; Santos, R.A.; Soares, R. Félix; Jesus, E.D. Costa; Sousa, G.M.

doi:10.1016/j.iotech.2022.100218

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies have reported otherwise with a higher SII being associated with worse OS; this is consistent with the findings of the present analysis, although it is recognized that these studies too had relatively smaller sample sizes. 13 , 34 , 35 …”

Section: Discussionmentioning

confidence: 99%

“…A higher NLR was suggested to be a marker of poorer overall survival (OS) and progression-free survival (PFS) in patients with metastatic RCC or melanoma 10 , 11 with a similar trend seen between higher SII values and survival outcomes in these patients. 12 , 13 It is well known how important inflammation is in the process of cancer development, and these markers are thought to be an indication of the body’s inflammatory status and thus have been investigated as indicators of prognosis. 14 , 15 , 16 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Anpalakhan,

Signori,

Cortellini

et al. 2023

iScience

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Anpalakhan,

Signori,

Cortellini

et al. 2023

iScience

View full text Add to dashboard Cite

“…In addition, other factors have been shown to potentially influence prognosis, namely inflammatory markers such as peripheral blood neutrophil/lymphocyte ratio and platelet count. These factors independently contribute to the systemic inflammatory index that correlates with worse outcomes [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…2 test of independence between treatment allocation (AM/PM) and toxicity grades; p-values and degrees of freedom (df) reported in parentheses. Gx: grade x; N/I: cases for which no information is available; overall toxicity corresponds to the maximum toxicity grade observed.…”

mentioning

confidence: 99%

Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes

Gonçalves

Esteban-Casanelles

et al. 2023

Cells

View full text Add to dashboard Cite

Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell death protein-1 and its ligand programmed death ligand 1. Concurrent retrospective studies suggest that morning infusions may lead to higher effectiveness of immune checkpoint inhibitors in melanoma, non-small cell lung cancer, and kidney cancer. This paper discusses the results of a retrospective study (2016–2022) exploring the impact of infusion timing on the outcomes of all 73 patients with stage IV melanoma receiving immunotherapy at a particular medical center. While the median overall survival (OS) was 24.2 months (95% confidence interval [CI] 9.04–39.8), for a median follow-up of 15.3 months, our results show that having more than 75% of infusions in the afternoon results in shorter median OS (14.9 vs. 38.1 months; hazard ratio 0.45 [CI 0.23–0.86]; p < 0.01) with more expressive impacts on particular subgroups: women, older patients, and patients with a lower tumor burden at the outset of immunotherapy. Our findings highlight the potential benefits of follow-up validation in prospective and translational randomized studies.

show abstract

114P Systemic inflammatory index as a prognostic biomarker in metastatic melanoma patients under immune checkpoint inhibitors

Cited by 2 publications

References 0 publications

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes

Contact Info

Product

Resources

About